top-home.jpg

The Business on ABC TV: Interview with Starpharma CEO Jackie Fairley

Starpharma expands its Drug Delivery Program with AstraZeneca

VivaGel®-coated condom approved for marketing in Japan

Starpharma receives $4.7M R&D tax incentives

Starpharma commences Dendrimer-Docetaxel clinical trial

Sexual Health Drug Delivery Agrochemicals Wider Applications
         
 

Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead sexual health product under development is VivaGel® (SPL7013 Gel), a vaginal microbicide to prevent the transmission of sexually transmitted infections (STIs) including HIV and genital herpes; and the management of bacterial vaginosis (BV). VivaGel® as a condom coating has been licensed with Ansell and Okamoto.

 

In the wider pharmaceutical and life science fields, Starpharma has specific programs in dendrimer drug delivery, including drug targeting, drug solubilisation, diagnostics and pharmaceutical excipients.

More broadly, Starpharma is exploring dendrimer opportunities in agrochemicals, cosmetics and materials science with applications as diverse as paints, coatings, adhesives, and water remediation.

 
         

invester-center.jpg

Code Last $+/-
SPL 0.735 0.005

Data provided by asx.com.au. Prices are delayed by at least 20 minutes.

© Starpharma Holdings Limited 2014